INCANDO THERAPEUTICS PARTICIPATES IN KEY PANEL DISCUSSION AT PRESTIGIOUS 24th HONG KONG FORUM
High-profile two-day event included top officials of Hong Kong and prominent business leaders
Dr. Charles Hu, Co-Founder of Incando Therapeutics Pte. Limited (“Incando”), joined other leading business minds earlier this week in a wide-ranging discussion on the future of healthcare innovation and investment in Hong Kong. The 24th Hong Kong Forum, hosted by the Hong Kong Trade Development Council (“HKTDC”), is the flagship event of Federation of Hong Kong Business Associations Worldwide, which represents over 11,000 business executives in 36 countries worldwide. The event was well-attended by prominent Hong Kong government leadership, and business leaders from around the globe.
“With the evolving healthcare landscape in the post-COVID era as the industry shifts its attention from immunotherapy towards neuroscience, neurodegeneration and digital therapeutics for elderly care, the Guangdong-Hong Kong-Macao Greater Bay Area (“GBA”) has a strong foundation in the research and development of geriatric medicine, molecular neuroscience and regenerative medicine which positions Hong Kong as a potential leader in this field.” Dr. Hu said at the panel discussion.
The panelists emphasized that with Hong Kong’s strategic location in GBA and the Asia-Pacific, Hong Kong offers unparalleled connectivity and accessibility across the healthcare industry in the East and West. Companies like Incando Therapeutics can take advantage of Hong Kong’s life sciences talent, and multiple world-class universities which offer rich collaboration opportunities. Incando Therapeutics currently has a research collaboration with the City University of Hong Kong, and is exploring others as well, in addition to clinical partnerships with Hong Kong and Greater Bay Area hospitals.
Incando is committed to being a part of the innovative life sciences ecosystem in Hong Kong, and is proud to participate in this renowned Forum. The company looks forward to further collaborations and initiatives with HKTDC and the Federation of Hong Kong Business Associations Worldwide that will contribute to Hong Kong’s growth as a leading hub for healthcare investment and innovation.
Moderator and Panelists (from left to right): Ms. Maggie Lee, Deputy Head of Greater Bay Area Strategy and Development Office, KPMG; Ms. Rachel Fan, CEO of G-NiiB GenieBiome; Dr. Charles Hu, Co-Founder of Incando Therapeutics; Dr. Kenneth Tsang, CEO of Gleneagles Hospital Hong Kong
Dr. Charles Hu, opining on the foundation and ecosystem within Hong Kong and the GBA for research and development of geriatric medicine, molecular neuroscience and regenerative medicine
ABOUT INCANDO THERAPEUTICS
Incando Therapeutics is an international biotechnology company developing next generation phototherapy solutions for grave diseases. With the mission of advancing photomedicine, Incando Therapeutics is currently developing treatments to improve quality of life and overall outcomes for patients navigating cancer and neurodegenerative disorders. For more information, visit https://incando.net/.
ABOUT DR. CHARLES HU
Dr. Charles Hu, PhD, Co-Founder and Chief Medical Affairs Officer.
A translational biomedical engineer with a passion in business development and investments, Charles’s vision is in bringing about a vibrant healthcare innovation and investment ecosystem in the HK Greater Bay Area. He obtained his PhD from Johns Hopkins University and his scientific expertise interfaces across biomedical engineering, regenerative medicine, interventional radiology, and materials science. He is also experienced in research commercialization and MNC pharma medical affairs. On the business front, Charles heads Ryoden Medical where he oversees healthcare venture investments, advises angel investors and startups, and actively engages in policy discussions in support of biomedical innovations and youth talent development.
Charles is a visiting Assistant Professor of Biomedical Sciences and Industrial Advisor of Biomedical Engineering at the City University of Hong Kong, vice president of the BIOHK international biotechnology conventions, board member of two biotechnology startups, advisor to the Asia Fund for Cancer Research of the National Foundation for Cancer Research, member of the Hong Kong Professionals and Senior Executives Association (HKPASEA) and the Hong Kong Biotechnology Organization (HKBIO), and director of several retail, food & beverage, and real estate businesses.
Incando Therapeutics 